Published online before print October 14, 2008, doi: 10.1161/CIRCHEARTFAILURE.108.790774
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Articles |
Detection of Endogenous B-Type Natriuretic Peptide at Very Low Concentrations in Patients With Heart Failure
From the Scios Inc (J.O., U.S.), Mountain View, Calif; Intrinsic Bioprobes Inc (E.E.N., U.A.K., R.W.N.), Tempe, Ariz; Christ Hospital (S.M., S.S.), Cincinnati, Ohio; and Medivation Inc (A.A.P.), San Francisco, Calif.
Correspondence to Ute Schellenberger, PhD, Pioneer HiBred International, Inc, 700 A Bay Road. Redwood City, CA 94063. E-mail uschellenberger{at}gmail.com
Received May 6, 2008; accepted September 23, 2008.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— The myocardium secretes B-type natriuretic peptide (BNP) in response to stimuli associated with heart failure (HF). However, high immunoreactive-BNP levels in patients with HF are associated with a paradoxical lack of natriuretic response. We hypothesized that commercially available assays for immunoreactive BNP do not reflect the bioactivity of the natriuretic peptide system, because they measure both unprocessed inactive pro-BNP and mature BNP 1-32. We describe an assay for the detection of bioactive BNP 1-32 and confirm very low concentrations in plasma from HF patients.
Methods and Results— We developed a quantitative mass spectrometry immunoassay to capture endogenous BNP peptides using high affinity antibodies. Bound BNP and its truncated fragments were detected by matrix assisted laser desorption ionization–time of flight mass spectrometry based on their predicted masses. Mass spectrometry immunoassay revealed rapid in vitro degradation of BNP 1-32 in plasma, which requires plasma collection in the presence of high protease inhibitor concentrations. In 11 of 12 HF patients BNP 1-32 was detectable, ranging from 25 to 43 pg/mL. Several degraded forms of BNP were also detected at similarly low levels. In contrast, parallel measurements of immunoreactive BNP using the Biosite assay ranged from 900 to 5000 pg/mL.
Conclusions— Detection of endogenous BNP 1-32 requires special preservation of plasma samples. Mass spectrometry immunoassay technology demonstrates that HF patients have low levels of BNP 1-32. Commercially available immunoreactive-BNP assays overrepresent biological activity of the natriuretic peptide system because they cannot distinguish between active and inactive forms. This observation may, in part, explain the "natriuretic paradox."
Key Words: natriuretic peptides • diagnosis • circulation • heart failure • mass spectrometry
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
B-type natriuretic peptide (BNP) is a cardiac hormone with mostly ventricular expression under conditions of volume overload and increased filling pressure.1–3 BNP is synthesized as a 108-aa propeptide and proteolytically processed to release an inactive 76-aa N-terminal fragment and bioactive mature BNP 1-32 into the bloodstream. Commercially available assays have proven utility for the diagnosis of heart failure (HF) with high specificity.4,5 At the same time, recombinant BNP 1-32 (nesiritide) has been approved for treatment of acute decompensated congestive HF; infusions of nesiritide lead to prompt symptomatic improvement in acutely ill HF patients.6,7 The seemingly paradoxical lack of natriuretic response to the high endogenous immunoreactive BNP (iBNP) levels as determined by commercially available assays has led investigators to hypothesize that altered and inactive circulating forms of BNP exist in HF patients.8–10 Indeed, experimental evidence suggests multiple molecular forms of BNP in HF patient plasma.11–14 Recent publications have shown that the intact precursor pro-BNP 1-108 is a major circulating component in HF patients, suggesting impaired processing mechanisms in the HF state.9,15 Moreover, pro-BNP has no16 or significantly reduced bioactivity compared with BNP 1-32,9 yet cross-reacts in commercial immunoassays because of common epitopes.9 Direct measurements of BNP 1-32 has been attempted by mass spectrometry17 and a combination of solid phase extraction, high-performance liquid chromatography, and immunodetection.11,12,18 Neither approach was able to detect the presence of the active BNP form, supporting the hypothesis of a somehow altered iBNP in HF patient samples. We describe a sensitive and quantitative mass spectrometry immunoassay (MSIA)19,20 to successfully measure BNP 1-32 in HF patients. We also present direct structural evidence for several proteolytically degraded forms of BNP in these patients. Further, we show that iBNP levels as detected by the Biosite Triage (Biosite Inc, San Diego, Calif) assay significantly overestimate the levels of bioactive, low molecular weight BNP, including BNP 1-32.
Clinical Perspective p 264
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
Protease inhibitors were from Calbiochem (4-(2-aminoethyl) benzenesulfonyl fluoride [AEBSF], benzamidine, pepstatin, H-Phe-Phe-Arg-chloromethylketone (PPACK II), protease inhibitor set III and VII) and Sigma (Leupeptin, aprotinin). The buffers HBS-N (0.01 mol/L HEPES, pH 7.4, containing 0.15 mol/L NaCl) and HBS-EP (0.01 mol/L HEPES, pH 7.4, containing 3 mmol/L EDTA, 0.15 mol/L NaCl, and 0.005% Tween20) were both from Biacore AB. Tween 20 and
-cyano-4-hydroxycinnamic acid were provided by Sigma-Aldrich. Sodium chloride, ammonium acetate, acetonitrile, trifluoroacetic acid, and ultrapure water were all purchased from American Bioanalytical, and n-octyl glucoside was from Roche Diagnostics. Recombinant human BNP 1-32 was from Scios, Inc. All other BNP peptides were synthesized by the American Peptide Company with >95% purity. The concentration of all peptide stock solutions was determined by amino acid analysis (UC Davis, Calif). Monoclonal mouse antibodies against human BNP, Mab 8.1 and Mab 106.3 were produced by Scios Inc. Mab 8.1 was described elsewhere and requires an intact C-terminus of BNP 1-32,9 whereas full-length BNP 1-32 was used to develop Mab 106.3 and the epitope was mapped to amino acids 5 to 13 (Jessica O’Rear, unpublished data, 2006).
Mass Spectrometry Immunoassay
MSIA protein extraction was achieved using antibody derivatized affinity pipettes (Intrinsic Bioprobes, Inc). These affinity pipettes or MSIA-Tips were produced as described previously.21 A mixture of equal concentrations (45 µg/mL) of Mabs 8.1 and 106.3 were used as the affinity ligand. For nonspecific MSIA affinity tips an unrelated antibody against antihuman β2-microglobulin (β2M, DakoCytomation) was coupled.
Plasma was thawed at room temperature and incubated at 37°C for 10 minutes. Warmed plasma was centrifuged at 5000g, 500 µL aliquots were transferred into a 96-well sample tray. Biotinylated BNP (bBNP) 1-32 was added to each well at a final concentration of 500 pg/mL to serve as an internal reference for MSIA.22 Samples were diluted 2-fold with HBS-EP, containing 1% Tween20 and 1 mol/L NaCl before MSIA.
Analyses of spiked standard curve samples, HF samples, and healthy control samples were performed in parallel. The workflow is depicted in Figure 1. Samples (1 mL) were first drawn 50 times through β2M affinity tips by automated aspiration/dispensing of 150 µL, followed by 300 times through BNP affinity tips. Next, each affinity tip was rinsed sequentially with HBS-EP, water, 25% acetonitrile in 2 mol/L ammonium acetate, 50 mmol/L n-octyl glucoside, and water (15 aspirations/dispenses at 150 µL for each step). Bound proteins were eluted from the affinity tip with 3.5 µL of matrix assisted laser desorption ionization (MALDI) matrix solution (6 mg/mL -cyano-4-hydroxycinnamic acid in acetonitrile/water (1:2 vol/vol) with 0.8% trifluoroacetic acid) and deposited directly onto the MALDI-target.22 Mass spectra were acquired for each eluent by summing six 250-laser shot acquisitions using a linear Bruker Autoflex MALDI–time of flight (TOF) mass spectrometer. Resulting mass spectra were batch processed in Flex Analysis 2.4 (Bruker Daltonics) to label all spectral peaks with a signal-to-noise >20 and to internally calibrate the m/z axis using bBNP. In addition, spectral intensities were normalized to the peak intensities of bBNP for intersample comparison and quantification. Peak lists, containing peak characteristics (m/z, signal-to-noise, normalized intensities) were imported into spreadsheets for data analysis.
|
Data Analysis
MSIA peak lists were screened for m/z values matching the m/z values calculated for theoretical BNP fragments. We assumed an intact disulfide bond between Cys15 and Cys26. We also considered Met oxidation in one or both positions as a possible posttranslational modification. Last, we based the hypothetical peak list on the specificity of Mabs 8.1 and 106.3 and their known epitopes. MSIA mass peaks with a signal-to-noise of
20 and a mass error of 
212 ppm, compared with the theoretical mass were identified. Mass error tolerance was calculated by dividing the difference between the theoretical mass and the experimental mass by the theoretical mass. For BNP peptides for which a standard curve was generated, concentrations were calculated based on their peak intensities normalized to the internal reference standard (IRS) bBNP.
Plasma Sample Collection
The study was approved by the Institutional Review Board at Christ Hospital, Cincinnati. Blood samples from 12 New York Heart Association functional class III and IV HF patients were collected into EDTA vacutainers and transferred immediately after centrifugation into storage tubes containing benzamidine and AEBSF (final inhibitor concentrations 10 mmol/L and 5 mmol/L, respectively) and stored at –70°C. Patients with Biosite Triage BNP assay results of >750 pg/mL were enrolled (Biosite Inc). Patient information is summarized in Table 1. Plasma from 10 consenting healthy volunteers was collected from the Lifescan Inc blood center (Milpitas, Calif) under identical conditions. Biosite Triage assay iBNP levels from these control subjects varied from <5 to 29 pg/mL.
|
The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Rapid Degradation of BNP 1-32 in Human Plasma
Previous evidence suggests that proteases in the circulation degrade BNP after secretion.21,22 We reasoned, therefore, that plasma collection conditions are crucial to preserve the structural integrity of any BNP forms that might be present in HF patients at the point of sampling. To study the kinetics of proteolytic degradation of BNP 1-32 in human plasma and the resulting degradation products, we developed a highly sensitive and quantitative MSIA.19,20 MSIA uses covalent solid phase coupling of 2 high-affinity monoclonal antibodies against different epitopes of BNP 1-32 to allow for the capture of C- and N-terminal truncated forms of BNP 1-32. The antibody loaded resin is contained within a small pipette tip, which is crucial for efficient binding, washing, and elution without significant sample loss. Eluted peptides are spotted directly onto a MALDI sample plate and analyzed. The principle of MSIA is depicted in Figure 1. Figure 2 shows the time course of BNP 1-32 degradation spiked at 10 ng/mL into heparin plasma from a healthy volunteer. Incubation was carried out at 37°C to simulate degradation in vivo. A rapid disappearance of the intact BNP 1-32 peptide can be observed. After 10 minutes the mass spectrum shows new peaks that can be assigned to BNP 3-32, BNP 1-30, BNP 3-30, BNP 3-29, and the isobaric pair BNP 1-29/4-31. As the starting material continues to be degraded, the ratio of BNP 3-32 and BNP 1-32 increases and new degradation products appear at 15 and 30 minutes, eg, BNP 4-29, BNP 5-29. After 1 hour almost no BNP 1-32 is detectable. Similar degradation was observed when BNP was spiked into whole blood, before plasma preparation and MSIA analysis (data not shown). We also tested BNP degradation in EDTA plasma, which had no effect on the rapid transformation of BNP 1-32 to 3-32, but slowed down further conversion significantly (data not shown). The same was true for incubation at 4°C, which slowed degradation only somewhat. We concluded that commonly used collection conditions are inefficient to prevent BNP 1-32 degradation during and after sample collection.
|
Inhibition of Protease Activity
BNP 1-32 was shown to be an efficient substrate for dipeptidyl peptidase IV, which leads to rapid formation of BNP 3-32 as assessed by mass spectrometry.23 In addition, Kallikrein-like activities have previously been implicated in the C-terminal degradation of BNP 1-32 as assessed by immunoassay.24 To minimize the effect of protease degradation after blood sampling we tested a broad range of inhibitors individually and in combination using MSIA. In a typical experiment 10 ng/mL of BNP 1-32 were added to normal EDTA plasma in the presence of 1 or several protease inhibitors. We found no or little effect of 0.5 mmol/L bestatin, 0.1 mmol/L pepstatin A, and up to 1 mmol/L E64. PPACK I and II at 1 mmol/L effectively prevented degradation at the C terminus but did not inhibit dipeptidyl peptidase activity at the N terminus. AEBSF, leupeptin, and benzamindine were tested up to 5 mmol/L individually and in various combinations. A mixture of AEBSF and leupeptin at 2.5 mmol/L each was determined to be most effective. An alternative inhibitor for leupeptin was benzamidine, 10 mmol/L of which prevented degradation of BNP 1-32 in combination with 5 mmol/L AEBSF. Figure 3A shows BNP 1-32 stability in EDTA plasma stored at room temperature in the presence of effective protease inhibitor concentrations for up to 2 hours. We also tested whether these protease inhibitors were effective when added 10 minutes after the addition of exogenous BNP 1-32 to allow for some degradation to BNP 3-32. Figure 3B shows long-term stability of such treated samples for up to 6 months, when stored at –70°C.
|
Quantitative MSIA Assay Development
Based on initial qualitative MSIA screening of HF patient plasma samples we synthesized BNP peptides with N- and C-terminal truncations. These peptides (BNP 1-32, BNP 3-32, BNP 2-31, BNP 4-32, BNP 5-32, BNP 5-31, BNP 4-30, and BNP 4-27) were added at equimolar concentrations to normal plasma to generate external standard curves for each peptide. MSIA achieved a sensitivity of 3.1 pmol/L for each peptide (lower level of quantification) with a signal-to-noise ratio of >35 even at the lowest concentration. This corresponds to roughly 10 pg/mL of BNP 1-32 and slightly lower pg/mL concentrations for the shorter peptides, depending on their molecular weights. Further, we included an N-terminally biotinylated BNP 1-32 (bBNP) at 500 pg/mL as an IRS to account for potential variations associated with both the affinity purification and MALDI processes. By choosing an IRS with a higher molecular weight compared with BNP 1-32, we avoided any overlap with naturally occurring BNP fragments in the mass spectrum. Figure 4A shows a typical standard curve for 3 of the 8 standard BNP peptides. We observed a nonlinear relationship, reflecting binding behavior of the BNP antibodies to the various BNP peptides during the MSIA process at very low peptide concentrations. Panel B depicts 4 mass spectra of the standard peptide mixture at 6.25, 25, 100, and 400 pmol/L, respectively. In all samples, the IRS was present at 500 pg/mL. Different ion intensities observed for different peptides relative to the IRS reflect different ionization efficiencies of each peptide and can thus be normalized.
|
Plasma Concentrations of BNP 1-32 and Related Fragments
After informed consent, we prospectively collected plasma with the inclusion of appropriate protease inhibitors benzamidine and AEBSF from 12 patients who had advanced HF. Each sample was analyzed by a 2-step MSIA as illustrated in Figure 1, with the inclusion of the IRS and external standard curves. We also analyzed 10 confirmed healthy donor samples. The resulting peak lists from all MSIA runs were scrutinized for the presence of predicted BNP-related peptides as described under Materials and Methods section. Mass peaks were assigned based on predicted masses for BNP peptide fragments. Of note, mass peaks observed in either the normal controls or the MSIA extractions using the control antibody could not be assigned to any BNP-related peptide, validating the high specificity of the MSIA approach with BNP monoclonal antibodies 8.1 and 106.3. Figure 5 shows representative mass spectra from 2 HF patients and 2 normal controls after BNP specific extraction. The quantitative results for all 12 HF samples are summarized in Table 2. In 11 of 12 patients we measured low levels of intact BNP 1-32 ranging from 25 to 43 pg/mL. BNP 3-32, BNP 4-32, and BNP 5-32 were present in all patients. In some patients, we detected small amounts of methionine-oxidized BNP 3-32, BNP 4-32, and BNP 5-32. BNP peptides with C-terminal truncations could also be assigned in 3 patients (Figure 5) but were not quantifiable because they were below the levels of quantification.
|
|
Comparison With Triage Biosite BNP Assay
Samples from all HF patients were analyzed using the Triage Biosite BNP assay at study enrollment and blood sample collection. Figure 6 highlights the differences between the iBNP concentrations obtained with the Biosite assay and the sum of all BNP fragments determined by MSIA. We did not include patients 2, 4, and 6 in this comparison, because we were unable to quantify the C-terminally truncated BNP peptides in these samples.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our data lend further support to the hypothesis that high levels of iBNP as measured in a commercial point of care (POC) assay do not reflect the bioactivity of the natriuretic peptide system. Yandle et al14 first showed the presence of circulating unprocessed pro-BNP 1-108 in HF patients. We and others found that recombinantly expressed pro-BNP has significantly reduced9 or no activity at all,16 and we provided Western blot evidence that pro-BNP constitutes a major plasma component in HF patients.9 Similarly, Seferian et al15 measured pro-BNP: BNP ratios of up to 10.8:1 in patients with HF. Further, because the epitopes are preserved in pro-BNP, we have also shown that at least 2 of the commercial POC assays for BNP cross-react with the inactive precursor.9 Other investigators have attempted direct detection of active BNP 1-32 using different extraction and detection methods, including mass spectrometry.11,17 In our study, we were able to quantify active BNP 1-32, for the first time, in 11 of 12 patients diagnosed with HF. Our unique approach to capture circulating BNP peptides with high affinity monoclonal antibodies, coupled with high sensitivity MALDI–TOF mass spectrometry detection allowed us to study the molecular complexity of BNP degradation in human plasma. We found that effective protease inhibition is crucial to preserve the structural integrity of BNP 1-32 during and after blood collection. Although commonly used EDTA anticoagulation tubes are sufficient to preserve iBNP,25–27 additional inhibitors in the millimolar range are required for complete protease inactivation. This may explain why other investigators were unable to detect and quantify BNP 1-32 in vivo.
The presence of BNP 3-32 attributable to action of dipeptidyl peptidases has been suggested,23 and we were able to detect this BNP analog in every single patient we studied. We also detected further proteolysed BNP peptides, eg, BNP 4-32, BNP 5-32, BNP 5-31, BNP 1-25, and BNP 1-26. We tested the bioactivity of each of these peptides in a cell-based assay measuring cGMP production9 and found no differences compared with BNP 1-32 (Jessica O’Rear, unpublished data, 2007). As has been shown for BNP 3-32, one can only speculate that even shorter peptides may have reduced natriuretic activity in vivo, despite their apparent in vitro activity.28 Even assuming activity, the sum of all BNP peptides measured in every patient by MSIA would still represent only a fraction of the total iBNP measured by the Biosite assay (Figure 6). The BNP antibodies used in our MSIA also bind pro-BNP. Although we verified that the presence of up to 10 ng/mL of recombinant pro-BNP does not interfere with the quantification of low molecular weight BNP forms, we were unable to quantify endogenous pro-BNP levels with this MSIA method (Eric Niederkofler, unpublished data, 2007). Mass spectrometry is uniquely suited to detect and quantify multiple forms of endogenous BNP, and our results highlight the need for more specific clinical immunoassays to address questions of abnormal pro-BNP processing and to provide an accurate measure of bioactive BNP concentrations.
The presence of BNP fragments with one oxidized methionine residue is also noteworthy. Although it is possible to introduce methionine oxidation during sample preparation and MALDI,29 we observed this modification only in patient samples and never in our standard peptides or spiked plasma samples. Posttranslational oxidation might be a reflection of oxidative stress, a hallmark of cardiac disease. The exact site and role of this modification needs to be further studied, but we have previously shown that modification of Met10 leads to inactivation of BNP 1-32 (Andy Protter, unpublished data, 2002).
In summary, the data from our study strongly suggest that concentrations of bioactive BNP 1-32 are very low in patients with symptomatic HF. Commercial POC assays measure very high iBNP levels presumably due to a large molar excess of cross-reacting unprocessed pro-BNP. Although the small patient number was insufficient to establish a relation between HF stage and specific hormone levels, our findings may help to explain the paradoxical lack of physiological natriuretic hormone response in HF patients, especially in the acutely decompensated state, and why infusion with bioactive BNP 1-32 (nesiritide) generally provides symptomatic relief.
|
Acknowledgments |
|---|
The authors thank Dr Roger Mills for critical reading of this manuscript, his helpful advice, and general support of this project. Further, the authors acknowledge Dr Jan Scardina and Pat Hummel for the production of monoclonal BNP antibodies 8.1 and 106.3.
Disclosures
Dr Menon is a consultant and shareholder of CHF Solutions Inc.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000; 2: 198–205.[Medline]
2. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003; 362: 316–322.[CrossRef][Medline]
3. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998; 339: 321–328.
4. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005; 330: 625.
5. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem. 2004; 50: 33–50.
6. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, Lui C, Chatterjee K. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999; 34: 155–162.
7. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000; 343: 246–253.
8. Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol. 2007; 49: 1193–1202.
9. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007; 49: 1071–1078.
10. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem. 2004; 50: 1503–1510.
11. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, Sugita K, Yamada K. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta. 2002; 316: 129–135.[CrossRef][Medline]
12. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta. 2003; 334: 233–239.[CrossRef][Medline]
13. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem. 2002; 48: 1035–1042.
14. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab. 1993; 76: 832–838.[Abstract]
15. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, Kara AN, Krasnoseslky MI, Apple FS, Esakova TV, Filatov VL, Katrukha AG. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem. 2007; 53: 866–873.
16. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007; 49: 1114–1119.
17. Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA. 2005; 102: 17442–17447.
18. Seidler T, Pemberton C, Yandle T, Espiner E, Nicholls G, Richards M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun. 1999; 255: 495–501.[CrossRef][Medline]
19. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA. 2005; 102: 10852–10857.
20. Kiernan UA. Quantitation of target proteins and post-translational modifications in affinity-based proteomics approaches. Expert Rev Proteomics. 2007; 4: 421–428.[CrossRef][Medline]
21. Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res. 2003; 44: 630–639.
22. Niederkofler EE, Tubbs KA, Gruber K, Nedelkov D, Kiernan UA, Williams P, Nelson RW. Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal Chem. 2001; 73: 3294–3299.[Medline]
23. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006; 52: 82–87.
24. Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AH, Bluestein BI. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta. 2004; 340: 163–172.[CrossRef][Medline]
25. Gobinet-Georges A, Valli N, Filliatre H, Dubernet MF, Dedeystere O, Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med. 2000; 38: 519–523.[CrossRef][Medline]
26. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med. 2004; 42: 942–944.[CrossRef][Medline]
27. Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci (Lond). 1999; 97: 689–695.[Medline]
28. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007; 292: R897–R901.
29. Hollemeyer K, Heinzle E, Tholey A. Identification of oxidized methionine residues in peptides containing two methionine residues by derivatization and matrix-assisted laser desorption/ionization mass spectrometry. Proteomics. 2002; 2: 1524–1531.[CrossRef][Medline]
 |
|
 |
|
  G. Boerrigter, L. C. Costello-Boerrigter, G. J. Harty, B. K. Huntley, A. Cataliotti, H. Lapp, and J. C. Burnett Jr. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2009; 296(6): R1744 - R1750. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||